Autosomal dominant polycystic kidney disease: the changing face of clinical management.
about
Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best PracticeA polycystin-centric view of cyst formation and disease: the polycystins revisitedThe Treatment of Autosomal Dominant Polycystic Kidney DiseaseAutosomal dominant polycystic kidney disease: recent advances in clinical managementPKD2 mutation in an Iranian autosomal dominant polycystic kidney disease family with misleading linkage analysis data.Healthcare resource consumption and cost of care among patients with polycystic kidney disease in Italy.The importance of total kidney volume in evaluating progression of polycystic kidney diseaseTemporal and geographical external validation study and extension of the Mayo Clinic prediction model to predict eGFR in the younger population of Swiss ADPKD patients.Lack of Benefit of Early Intervention with Dietary Flax and Fish Oil and Soy Protein in Orthologous Rodent Models of Human Hereditary Polycystic Kidney DiseaseDelayed diagnosis of Townes-Brocks syndrome with multicystic kidneys and renal failure caused by a novel SALL1 nonsense mutation: A case report.A mild reduction of food intake slows disease progression in an orthologous mouse model of polycystic kidney diseaseKidney Organoids: A Translational Journey.Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease.KHA-CARI guideline recommendations for the diagnosis and management of autosomal dominant polycystic kidney disease.Metformin Inhibits Cyst Formation in a Zebrafish Model of Polycystin-2 Deficiency.Is Regular Screening for Intracranial Aneurysm Necessary in Patients with Autosomal Dominant Polycystic Kidney Disease? A Systematic Review and Meta-analysis.Endoglin controls blood vessel diameter through endothelial cell shape changes in response to haemodynamic cues.B-type natriuretic peptide overexpression ameliorates hepatorenal fibrocystic disease in a rat model of polycystic kidney disease.Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial.PKD2-Related Autosomal Dominant Polycystic Kidney Disease: Prevalence, Clinical Presentation, Mutation Spectrum, and Prognosis.Roles of mTOR complexes in the kidney: implications for renal disease and transplantation.ADPKD: clinical issues before and after renal transplantation.The Clinical Manifestation and Management of Autosomal Dominant Polycystic Kidney Disease in China.Clinical Manifestation and Management of ADPKD in Western Countries.Defective glycolysis and the use of 2-deoxy-D-glucose in polycystic kidney disease: from animal models to humans.Polycystin and calcium signaling in cell death and survival.Generation and phenotypic characterization of Pde1a mutant mice.Rapamycin treatment dose-dependently improves the cystic kidney in a new ADPKD mouse model via the mTORC1 and cell-cycle-associated CDK1/cyclin axis.Proteomics of Urinary Vesicles Links Plakins and Complement to Polycystic Kidney Disease.Long-Term Outcomes in Patients with Very-Early Onset Autosomal Dominant Polycystic Kidney Disease.Genetic diagnosis of autosomal dominant polycystic kidney disease: linkage analysis versus direct mutation analysis.The vasopressin system: new insights for patients with kidney diseases: Epidemiological evidence and therapeutic perspectives.Editor's introduction--genetic polymorphisms and clinical heterogeneities.Tolerability of Aquaretic-Related Symptoms Following Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Results From TEMPO 3:4.European ADPKD Forum multidisciplinary position statement on autosomal dominant polycystic kidney disease care: European ADPKD Forum and Multispecialist Roundtable participants.Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease.Genetic Complexity of Autosomal Dominant Polycystic Kidney and Liver Diseases.Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial.Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial.Validation of Surrogates of Urine Osmolality in Population Studies.
P2860
Q26767011-242DF013-B201-4502-A848-107E43213944Q26800974-2564B666-8D14-4E09-A114-C5B2FAFB2C83Q28077060-D316E717-6D3B-4955-87D8-A3C7AA7009F0Q28079782-258D1197-8615-4263-86CD-294DC472AEDCQ31111757-303BB60D-0FAA-4F01-8DFE-C6D9D5578068Q33627670-DDFE36B1-58AC-42ED-9605-38C5EBB09698Q33873107-BE2BD133-7930-49FA-B717-362770BEAD4FQ33910788-C5F22C23-B731-4AD1-A159-7E88F5C7638CQ36026246-C26820BB-14AF-463C-A482-1EFF98255683Q36741767-615AFE1D-9EFC-4532-94C0-1E68779C117DQ36810726-EC412D72-0801-4FF3-BE6E-502D1F0C1791Q38558317-488F33DF-5247-468D-B613-F1AF5FC2FFF5Q38593001-570A8289-2019-4720-9856-BF62BD7F6D46Q38618900-A46B1669-5217-46C0-9468-5B312495DCB6Q38645850-5C8EC9E2-655F-4752-9647-B0B8C5B4779BQ38684063-C5C70222-3367-464E-A69C-D7EC7BEB9620Q38771567-DB938FC9-DB84-4920-9FE1-518A1E9E73E2Q38833791-4B8776B3-9BFA-4839-840A-7E963FC7C990Q38853071-5F3C79BA-1A51-43BE-810E-42B0CC7637BFQ38868452-57A56504-BA5C-4F95-8B9D-E1ACAFB3EACDQ38914374-6AC50832-B64C-4A8D-BB2F-9DCC8CD3A8FBQ38987102-C1F4A173-3973-4697-8C8A-D2446D111784Q39030252-0DF2CD5A-2D5D-426C-808F-D8B1586ADF9AQ39030254-6EA64A59-6C2A-4A62-A773-4E8BE6A2CF44Q39228045-27AE5870-1AFA-434A-9A3C-DDBC2469268EQ39364250-E973656E-3C82-4540-92E9-F305272C2473Q41153428-8044CAD4-7A1E-4C30-927D-826B82967DDCQ41247634-2EFB11EB-FC0A-4BB7-BEF7-4AB18DDF4AFCQ41645528-1FB110D5-42BD-447B-9FD8-9325DFD14367Q41823915-57BB15D0-C102-49F1-8EF3-9D6294E9CAE4Q41947887-ED4F967B-6684-4DB2-9293-0BE02BE16CD4Q41998074-1629B034-46F5-426C-A779-E59A977CCBAFQ43229355-318CBC54-121C-4A3F-A26A-CD15F481A2D2Q47110579-A325F6D9-5C08-4D32-9267-C1DF2E1D18F5Q47564027-05825406-BD0A-411D-B8CB-8968BC5C8349Q47666190-AD801F61-A463-4DD3-B71C-6DDB1F1D48DCQ47781166-15AF11C1-0AC5-4FCF-9E53-D99A7B262549Q47907872-BEE11840-B26E-40ED-A8EE-B587424CDFD2Q47925751-71583E8B-1835-436F-B5A5-74119069BE64Q48015191-DB6AC2E4-5DA2-476D-AD94-8C98ED22FCBD
P2860
Autosomal dominant polycystic kidney disease: the changing face of clinical management.
description
2015 nî lūn-bûn
@nan
2015 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Autosomal dominant polycystic kidney disease: the changing face of clinical management.
@ast
Autosomal dominant polycystic kidney disease: the changing face of clinical management.
@en
Autosomal dominant polycystic kidney disease: the changing face of clinical management.
@nl
type
label
Autosomal dominant polycystic kidney disease: the changing face of clinical management.
@ast
Autosomal dominant polycystic kidney disease: the changing face of clinical management.
@en
Autosomal dominant polycystic kidney disease: the changing face of clinical management.
@nl
prefLabel
Autosomal dominant polycystic kidney disease: the changing face of clinical management.
@ast
Autosomal dominant polycystic kidney disease: the changing face of clinical management.
@en
Autosomal dominant polycystic kidney disease: the changing face of clinical management.
@nl
P2093
P1433
P1476
Autosomal dominant polycystic kidney disease: the changing face of clinical management.
@en
P2093
Albert C M Ong
Bertrand Knebelmann
ERA-EDTA Working Group for Inherited Kidney Diseases
P304
P356
10.1016/S0140-6736(15)60907-2
P407
P577
2015-05-01T00:00:00Z